Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wiese

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Expert Opinion on Therapeutic Patents|August 21, 2015
BCRP/ABCG2 inhibitors: a patent review (2009-present)Michael Wiese
Current Pharmaceutical Design|September 29, 2012
Accessing cancer metabolic pathways by the use of microarray technologyMartin Koch, Michael Wiese
Bioorganic & Medicinal Chemistry Letters|September 29, 2012
4-Substituted-2-phenylquinazolines as inhibitors of BCRPKapil Juvale, Michael Wiese
Molecular Informatics|August 4, 2016
In Memoriam: Prof. Dr. Joachim K. SeydelIlza Pajeva, Michael Wiese
Microarrays (Basel, Switzerland)|September 9, 2016
Quality Visualization of Microarray Datasets Using CircosMartin Koch, Michael Wiese
Journal of Computer-Aided Molecular Design|November 25, 2006
Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243Christian Hallmen, Michael Wiese
Chemmedchem|February 23, 2012
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathwayAnne Pick, Michael Wiese
Journal of Cancer Research and Clinical Oncology|October 12, 2012
Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancerMartin Koch, Michael Wiese
Future Medicinal Chemistry|August 22, 2015
Design of inhibitors of BCRP/ABCG2Kapil Juvale, Michael Wiese
Journal of Medicinal Chemistry|October 31, 2003
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivityRomy Fleischer, Michael Wiese
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Expert Opinion on Therapeutic Patents|August 21, 2015
BCRP/ABCG2 inhibitors: a patent review (2009-present)Michael Wiese
Current Pharmaceutical Design|September 29, 2012
Accessing cancer metabolic pathways by the use of microarray technologyMartin Koch, Michael Wiese
Bioorganic & Medicinal Chemistry Letters|September 29, 2012
4-Substituted-2-phenylquinazolines as inhibitors of BCRPKapil Juvale, Michael Wiese
Molecular Informatics|August 4, 2016
In Memoriam: Prof. Dr. Joachim K. SeydelIlza Pajeva, Michael Wiese
Microarrays (Basel, Switzerland)|September 9, 2016
Quality Visualization of Microarray Datasets Using CircosMartin Koch, Michael Wiese
Journal of Computer-Aided Molecular Design|November 25, 2006
Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243Christian Hallmen, Michael Wiese
Chemmedchem|February 23, 2012
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathwayAnne Pick, Michael Wiese
Journal of Cancer Research and Clinical Oncology|October 12, 2012
Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancerMartin Koch, Michael Wiese
Future Medicinal Chemistry|August 22, 2015
Design of inhibitors of BCRP/ABCG2Kapil Juvale, Michael Wiese
Journal of Medicinal Chemistry|October 31, 2003
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivityRomy Fleischer, Michael Wiese
Pageof 12